ANDRE NEDER RAMIRES ABDO
Índice h a partir de 2011
8
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
16 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 16
- Cardiac Tamponade as the First Manifestation of Erdheim-Chester Disease(2020) COSTA, Isabela B. S. da S.; COSTA, Fernanda A. de S.; BITTAR, Cristina S.; RIZK, Stephanie I.; ABDO, Andre N. R.; SIQUEIRA, Sheila A. C.; ROCHA, Vanderson; PEREIRA, Juliana; KY, Bonnie; HAJJAR, Ludhmila A.
- MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial(2021) SEGURO, Fernanda S.; MACIEL, Felipe V. R.; SANTOS, Fernanda M.; ABDO, Andre N. R.; PEREIRA, Thales D. M.; NARDINELLI, Luciana; ROCHA, Vanderson; BENDIT, IsraelBackground: Treatment-free survival (TFS) in chronic myeloid leukemia (CML) is a new goal. This prospective study aims to evaluate imatinib discontinuation's feasibility and safety in patients with deep molecular response MR4 (BCR-ABL1 < 0.01 % IS). Methods: Study was approved by the ethical committee and registered at Clinicaltrials.gov (NCT03239886). Incluision criteria were: age >= 18y, chronic phase, first-line imatinib for 36 months, MR4 for 12 months, no previous transplant or resistance. Imatinib was resumed when two samples confirmed the loss of MMR. The primary endpoint was molecular recurrence-free survival (MRFS) at 24 months. Lymphocyte subpopulations were counted in peripheral blood before discontinuation. Results: 31 patients were included from Dec/2016 until Oct/2017. Median age was 54years, 58 % male, 58 % low Sokal, 65 % b3a2 transcripts, and 61 % were in MR4.5. Imatinib therapy's median time was 9.7y (3-14.9 y), median time of MR4 was 6.9y (1.6-10.3y). MRFS at 24 months was 55 % (95 % CI 39-75). Thirteen patients relapsed, 46 % after six months of discontinuation, and all patients recovered MMR. Median time to recover MMR was one month. MR4.5 was the only factor associated with MRFS. NK cells proportion at baseline was lower in patients with only MR4 who relapsed after discontinuation. Conclusion: With a median duration of sustained MR4 above five years, as recommended by most TKI discontinuation guidelines, the TFS was similar to previous studies. Only MR4.5 was associated with lower risk of relapse. Further studies are needed to evaluate whether patients with only MR4 and low NK cell levels are suitable for discontinuation.
article 20 Citação(ões) na Scopus Efficacy and Safety Results From ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With >= 2 Tyrosine Kinase Inhibitors(2021) HOCHHAUS, Andreas; BOQUIMPANI, Carla; REA, Delphine; MINAMI, Yosuke; LOMAIA, Elza; VOLOSHIN, Sergey; TURKINA, Anna G.; KIM, Dong-Wook; APPERLEY, Jane; CORTES, Jorge E.; ABDO, Andre; FOGLIATTO, Laura Maria; KIM, Dennis Dong Hwan; COUTRE, Philipp D. le; SAUSSELE, Susanne; ANNUNZIATA, Mario; HUGHES, Timothy P.; CHAUDHRI, Naeem A.; CHEE, Lynette C. Y.; GUTIERREZ, Valentin Garcia; SASAKI, Koji; AIMONE, Paola; ALLEPUZ, Alex; QUENET, Sarah; BEDOUCHA, Veronique; MAURO, Michael J.- Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL(2023) HOCHHAUS, Andreas; REA, Delphine; BOQUIMPANI, Carla; MINAMI, Yosuke; CORTES, Jorge E.; HUGHES, Timothy P.; APPERLEY, Jane F.; LOMAIA, Elza; VOLOSHIN, Sergey; TURKINA, Anna; KIM, Dong-Wook; ABDO, Andre; FOGLIATTO, Laura Maria; COUTRE, Philipp le; SASAKI, Koji; KIM, Dennis Dong Hwan; SAUSSELE, Susanne; ANNUNZIATA, Mario; CHAUDHRI, Naeem; CHEE, Lynette; GARCIA-GUTIERREZ, Valentin; KAPOOR, Shruti; ALLEPUZ, Alex; QUENET, Sara; BEDOUCHA, Veronique; MAURO, Michael J.Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) treated with >= 2 prior tyrosine kinase inhibitors (TKIs). In ASCEMBL, patients with CML-CP treated with >= 2 prior TKIs were randomized (stratified by baseline major cytogenetic response [MCyR]) 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily. Consistent with previously published primary analysis results, after a median follow-up of 2.3 years, asciminib continued to demonstrate superior efficacy and better safety and tolerability than bosutinib. The major molecular response (MMR) rate at week 96 (key secondary endpoint) was 37.6% with asciminib vs 15.8% with bosutinib; the MMR rate difference between the arms, after adjusting for baseline MCyR, was 21.7% (95% CI, 10.53-32.95; two-sided p = 0.001). Fewer grade >= 3 adverse events (AEs) (56.4% vs 68.4%) and AEs leading to treatment discontinuation (7.7% vs 26.3%) occurred with asciminib than with bosutinib. A higher proportion of patients on asciminib than bosutinib remained on treatment and continued to derive benefit over time, supporting asciminib as a standard of care for patients with CML-CP previously treated with >= 2 TKIs.
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs(2021) REA, Delphine; MAURO, Michael J.; BOQUIMPANI, Carla; MINAMI, Yosuke; LOMAIA, Elza; VOLOSHIN, Sergey; TURKINA, Anna; KIM, Dong-Wook; APPERLEY, Jane F.; ABDO, Andre; FOGLIATTO, Laura Maria; KIM, Dennis Dong Hwan; COUTRE, Philipp le; SAUSSELE, Susanne; ANNUNZIATA, Mario; HUGHES, Timothy P.; CHAUDHRI, Naeem; SASAKI, Koji; CHEE, Lynette; GARCIA-GUTIERREZ, Valentin; CORTES, Jorge E.; AIMONE, Paola; ALLEPUZ, Alex; QUENET, Sara; BEDOUCHA, Veronique; HOCHHAUS, AndreasPatients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to >= 2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to approved TKIs. In this phase 3, open-label study, patients with CML-CP previously treated with >= 2 TKIs were randomized (2:1) to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily. Randomization was stratified by major cytogenetic response (MCyR) status at baseline. The primary objective was to compare the major molecular response (MMR) rate at week 24 for asciminib vs bosutinib. A total of 233 patients were randomized to asciminib (n = 157) or bosutinib (n = 76). Median follow-up was 14.9 months. The MMR rate at week 24 was 25.5% with asciminib and 13.2% with bosutinib. The difference in MMR rate between treatment arms, after adjusting for MCyR at baseline, was 12.2% (95% confidence interval, 2.19-22.30; 2-sided P = .029). Fewer grade >= 3 adverse events (50.6% vs 60.5%) and adverse events leading to treatment discontinuation (5.8% vs 21.1%) occurred with asciminib than with bosutinib. The study showed a superior efficacy of asciminib compared with that of bosutinib, together with a favorable safety profile. These results support the use of asciminib as a new therapy in patients with CML-CP who are resistant/intolerant to >= 2 prior TKIs.
- Cardiovascular Manifestations of Erdheim-Chester's Disease: A Case Series(2018) COSTA, Isabela Bispo Santos da Silva; ABDO, Andre Neder Ramires; BITTAR, Cristina Salvadori; FONSECA, Silvia Moulin Ribeiro; MORAES, Aline Sabrina Holanda Teixeira; KALIL FILHO, Roberto; PEREIRA, Juliana; HAJJAR, Ludhmila AbrahaoErdheim-Chester Disease is a rare entity, classified as an inflammatory myeloid neoplasm, with an unknown incidence, occurring preferentially in men after 50 years of age. Classically, it has a multisystemic presentation, with the skeletal system being the most frequently affected (90% of the patients), followed by genitourinary involvement in 60% of cases and central nervous system in the pituitary and diabetes insipidus in 25% of the cases. Cardiovascular manifestations are present in more than half of the patients, with aortic infiltration and atrial pseudotumor being the most common forms.
- How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation(2020) PERINI, Guilherme Fleury; FISCHER, Thais; GAIOLLA, Rafael Dezen; ROCHA, Talita Bueno; BELLESSO, Marcelo; TEIXEIRA, Larissa Lane Cardoso; DELAMAIN, Marcia Torresan; SCHELIGA, Adriana Alves de Souza; RIBEIRO, Glaciano Nogueira; NETO, Jorge Vaz; BAIOCCHI, Otavio Cesar Carvalho Guimaraes; ABDO, Andre Neder Ramires; ARRAIS-RODRIGUES, Celso; FOGLIATTO, Laura M.; BIGNI, Ricardo de Sa; SCHAFFEL, Rony; BIASOLI, Irene; PEREIRA, Juliana; NABHAN, Samir Kanaan; SOUZA, Carmino Antonio de; CHIATTONE, Carlos SergioThe novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease, including a higher risk of intensive care unit (ICU) admission, need for invasive ventilation or death. Management of patients with lymphoid malignancies can be challenging during the outbreak, due to need of multiple hospital visits and admissions, immunosuppression and need for chemotherapy, radiotherapy and stem cell transplantation. In this article, we will focus on the practical management of patients with lymphoid malignancies during the COVID-19 pandemic, focusing on minimizing the risk for patients. (C) 2020 Published by Elsevier Editora Ltda. on behalf of Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular.
- Clinical, laboratory and genetic features of Erdheim-Chester disease patients: analysis of a retrospective cohort of two reference centers in Latin America(2022) BRANDAO, Antonio Adolfo Guerra Soares; ABDO, Andre Ramires Neder; LAGE, Luis Alberto de Padua Covas; FATOBENE, Giancarlo; PEREIRA, Juliana; ROCHA, VandersonObjectives and Methods: Erdheim-Chester disease (ECD) is a rare histiocytic neoplasm with a heterogeneous clinical course, ranging from localized and asymptomatic bone lesions to a multisystem disease, causing significant morbidity and mortality. There are few cohorts published, mainly from North America and Europe. We retrospectively collected clinical data on sixteen biopsy-proven ECD patients diagnosed and treated at two Brazilian reference centres for histiocytic disorders from January 2006 to February 2020. Results: Median time from onset of symptoms to diagnosis was 13 months (0.1-142). The main organ involved in ECD was bone (75%) and also 75% of the patients presented involvement of more than one organ, characterizing a multi-organic form. BRAF status was available in 81.2% of patients and BRAF V600E mutation was detected by Sanger sequencing in only 18.8%, which can be explained by the low sensitivity of this technique. All patients were treated due to symptomatic disease and a median of two lines (range: 1-7) of therapy were needed. The most common first-line therapy used was alpha-interferon (75%). The median progression-free survival was 7.5 months, and the median OS was not reached. Discussion and Conclusion: In the largest Latin American cohort of patients with ECD reported to date, we observed findings which resemble demographic characteristics, sites of involvement and treatment choices reported by other groups. The outcomes may be better with target therapies such as BRAF and MEK inhibitors in patients with mutation and with the adoption of recently published consensus recommendations for the management of ECD patients.
- Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era(2020) GOYAL, Gaurav; HEANEY, Mark L.; COLLIN, Matthew; COHEN-AUBART, Fleur; VAGLIO, Augusto; DURHAM, Benjamin H.; HERSHKOVITZ-ROKAH, Oshrat; GIRSCHIKOFSKY, Michael; JACOBSEN, Eric D.; TOYAMA, Kazuhiro; GOODMAN, Aaron M.; HENDRIE, Paul; CAO, Xin-xin; ESTRADA-VERAS, Juvianee I.; SHPILBERG, Ofer; ABDO, Andre; KUROKAWA, Mineo; DAGNA, Lorenzo; MCCLAIN, Kenneth L.; MAZOR, Roei D.; PICARSIC, Jennifer; JANKU, Filip; GO, Ronald S.; HAROCHE, Julien; DIAMOND, Eli L.Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to nonspecific inflammatory and fibrotic findings on histopathologic review of tissue specimens. Additionally, the association of ECD with unusual tissue tropism and an insidious onset often results in diagnostic errors and delays. Most patients with ECD require treatment, except for a minority of patients with minimally symptomatic single-organ disease. The first ECD consensus guidelines were published in 2014 on behalf of the physicians and researchers within the Erdheim-Chester Disease Global Alliance. With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600-mutant ECD, there is a need for updated clinical practice guidelines to optimize the diagnosis and treatment of this disease. This document presents consensus recommendations that resulted from the International Medical Symposia on ECD in 2017 and 2019. Herein, we include the guidelines for the clinical, laboratory, histologic, and radiographic evaluation of ECD patients along with treatment recommendations based on our clinical experience and review of literature in the molecular era.
- Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring(2021) SEGURO, Fernanda Salles; SILVA, Carolina Maria Pinto Domingues Carvalho; MOURA, Carla Maria Boquimpani de; CONCHON, Monika; FOGLIATTO, Laura; FUNKE, Vaneuza Araujo Moreira; ABDO, Andre; MACEDO, Ariane Vieira Scarlatelli; SANTOS, Marilia Harumi Higushi dos; SARAIVA, Jose Francisco KerrThis manuscript summarizes the results of the consensus meeting composed of hematol-ogists and cardiologists to establish recommendations for the prevention and follow-up of cardiovascular (CV) risk in patients with chronic myeloid leukemia (CML) treated with BCR-ABL tyrosine kinase inhibitors (TKIs) from the point of view of clinical practice and from the perspective of hematology consultation. In the first medical appointment, the CV risk factors should be identified to perform the baseline risk stratification, based on the Brazilian Guideline of Dyslipidemia and Atheroscle-rosis Prevention Update (risk levels: very high, high, intermediate and low). Once stratified, the treatment of the CV risk factors should be administered. If the patient presents risk factors, such as hypertension, diabetes, renal disease, smoking and hyperc- holesterolemia, the evaluation and initial treatment may be done by the hematologist, being an option the request for evaluation by a specialist. If the patient has a history of previous CV disease, we recommend referral to a specialist. As the CV risk score is dynamic and the control of risk factors can reduce the patient risk, this expert consensus recommends that the re-evaluation of the CV risk after the baseline should be performed at 3 months, 6 months and 12 months. After this period, it should be done annually and, for specific patients, at the clinician's discretion. The evaluation of the baseline CV risk and the safe administration of a TKI allow the patient to benefit from the maximum treatment, avoiding unwanted effects. (C) 2020 Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular.